Therapeutic administration of inhaled INS1009, a treprostinil prodrug formulation, inhibits bleomycin-induced pulmonary fibrosis in rats

• Published in: Pulmonary pharmacology & therapeutics Vol. 49; pp. 95 - 103
• Main Authors: Corboz, Michel R., Zhang, Jimin, LaSala, Daniel, DiPetrillo, Keith, Li, Zhili, Malinin, Vladimir, Brower, Jeremy, Kuehl, Philip J., Barrett, Ted E., Perkins, Walter R., Chapman, Richard W.
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.04.2018
• Subjects: Administration, Inhalation; Animals; Antihypertensive Agents - administration & dosage; Antihypertensive Agents - pharmacokinetics; Antihypertensive Agents - pharmacology; Bleomycin - administration & dosage; Bleomycin - toxicity; Cells, Cultured; Disease Models, Animal; Dose-Response Relationship, Drug; Epoprostenol - administration & dosage; Epoprostenol - analogs & derivatives; Epoprostenol - pharmacokinetics; Epoprostenol - pharmacology; Fibroblasts; Fibroblasts - drug effects; Fibroblasts - metabolism; Hexadecyl-treprostinil; Humans; Hydroxyproline - metabolism; Idiopathic Pulmonary Fibrosis - drug therapy; Idiopathic Pulmonary Fibrosis - physiopathology; Inhalation treatment; INS1009; Lipids - chemistry; Male; Nanoparticles; Prodrugs; Pulmonary fibrosis; Pyridones - pharmacology; Rats; Rats, Inbred F344; Real-Time Polymerase Chain Reaction; Fibroblasts; Rats; Hexadecyl-treprostinil; Pulmonary fibrosis; Inhalation treatment; INS1009

Idiopathic pulmonary fibrosis is a progressive and lethal disease and while there are now two approved drugs (Esbriet® and Ofev®) additional effective treatments are still needed. Recently, prostacyclin analogs such as iloprost and treprostinil (TRE) have been shown to exert some protection against...